NMPA Approves 39 Generic Drug Products Including First-time Evaluations for Eltrombopag Ethanolamine Tablets, Diazoxide Oral Suspension, and Lithium Carbonate Tablets

Jan 16, 2024 20:31 CST Updated 20:31

CHIATAI TIANQING

High-quality pharmaceuticals research, production, and sales provider

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

Kelun

Innovative Pharmaceutical R&D Company

Shijiazhuang No.4 Pharmaceutical Co.,Ltd.

Manufacturers and Service Providers of Chemical Drugs and Traditional Chinese Medicine

Huahai Pharmaceutical

Medical and Health Product Provider

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements. This article only introduces drugs related to medical health, not a recommendation of treatment plans (if involved), and does not represent the platform's position. Any article reprints require authorization.

Today, according to the delivery information of the drug approval certificates released by NMPA, 39 varieties(58 Specifications)The latest approval involves multiple pharmaceutical companies, including CHIATAI TIANQING, Qilu Pharmaceutical, Kelun, Shijiazhuang No.4 Pharmaceutical Co.,Ltd., Huahai Pharmaceutical, and Nanjing Haichen Pharmaceutical Co.,Ltd.

Among whichEltrombopag Ethanolamine TabletsWelcomeCHIATAI TIANQING, Qilu Pharmaceutical, Kelun, and Jiangsu Aosaikang Pharmaceutical Co.,Ltd. were approved on the same day.This time,Eltrombopag Ethanolamine Tablets, Diazoxide Oral Suspension, and Lithium Carbonate Tablets are the first three varieties to pass the evaluation.See the table and mini-program below for details.

List of Products Passed Evaluation on January 16 (First to Pass Marked in Red)

Data Source:PharmCube Approved Drug Summary Database

END

This article is original. Please leave a message to obtain authorization for reprint.

Recent Popular Resource Acquisition

Reply to the keyword "Report", access dozens of exclusive reports produced by Yaorongyun
Reply to the keyword "CSCO", Obtain 2023 CSCO Guidelines
Reply to the keyword "ASCO", Obtain 2023 ASCO Abstract by Cancer Type
Reply to the keyword "First Generic in 2022", obtain the list of first generic drugs approved in 2022
Reply to the keyword "Medical Insurance", Obtain the 2022 Medical Insurance Catalog

Contact us to experience more professional services from PharmaCloud.

WillDiscussion

CombineWork

GardenDistrict

TakeWu

Database

Consultation

Customization

Service

Media

Cooperation

ClickReadRead the Original Text, apply for a free trial of PharmaCloud Enterprise Edition!